New CEO Alexander Hardy is wasting no time overhauling rare disease specialist BioMarin, with the company’s chief commercial officer now headed for the exits. Jeffrey Ajer, who’s been with the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback